ENTA
Enanta Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
10.71
close · 2026-10-30
value
21
cheaper than peers21
quality
31
stronger fundamentals31
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.51× | 72 |
| price to book | 3.09× | 52 |
| cash flow yield, latest year | -10.3% | 49 |
| earnings yield, 3 years ago | -55.2% | 29 |
| earnings yield, latest year | -35.9% | 29 |
| earnings yield, 2 years ago | -59.6% | 25 |
| cash flow yield, 3 years ago | -27.9% | 25 |
| cash flow yield, 1 year ago | -31.0% | 24 |
| earnings yield, 1 year ago | -51.2% | 24 |
| cash flow yield, 2 years ago | -36.0% | 24 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -69.1% | 59 |
| revenue growth | 15.0% | 47 |
| return on equity | -59.0% | 43 |
| debt to equity | 160.1% | 15 |
4 of 4 measures available
Facts
| market cap | $312M |
| free cash flow | $7.7M |
| employees | 120 |
| first trade | 2013-03-21 |
| next earnings | not reported |
| fundamentals updated | 2026-07-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -3.84 | -5.48 | -6.38 | -5.91 | not reported |
| free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | not reported |
| net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | not reported |
| revenue | $65.3M | $67.6M | $79.2M | $86.2M | not reported |
| unusual items | $39,000 | $73,000 | not reported | $83,000 | -$27,000 |